NHS Greater Glasgow and Clyde

Running trials

• Not yet recruiting

  The Efficacy and Safety Study of 2107 Injection in Subjects With Mild to Moderate Knee Osteoarthritis

  NCT07746843· BioRegen Biomedical (Changzhou) Co., Ltd· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  Breath Research Narrow Validation for Gastrointestinal Cancer Detection

  NCT07714538· Imperial College London· Source

• Recruiting

  Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

  NCT07443956· NHS Greater Glasgow and Clyde· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Active, not recruiting

  Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography

  NCT03952351· University of Edinburgh· Source

• Recruiting

  Feasibility of a Physiotherapy Programme, With Integrated telerehabIlitation to Increase Rehabilitation Time and Improve Motor Function

  NCT06871878· Glasgow Caledonian University· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis

  NCT06940531· Alexander Horsley· Source

• Not yet recruiting

  NanO2 in Large VessEL Occlusion Stroke (NOVEL)

  NCT06821347· Phase 2· NHS Greater Glasgow and Clyde· Source

• Recruiting

  A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

  NCT06735248· Phase 2· ModernaTX, Inc.· Source

• Active, not recruiting

  A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

  NCT06717126· Phase 2· iOnctura· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· ETOP IBCSG Partners Foundation· Source

• Recruiting

  SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  NCT06743126· Phase 3· Immatics US, Inc.· Source

• Not yet recruiting

  The U.K. NorthStar Clinical Network

  NCT06711692· University College, London· Source

• Active, not recruiting

  Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

  NCT06531109· Pfizer· Source

• Active, not recruiting

  A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

  NCT06294925· Pfizer· Source

• Active, not recruiting

  Radiograph Accelerated Detection and Identification of Cancer in the Lung

  NCT06044454· NHS Greater Glasgow and Clyde· Source

• Recruiting

  A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  NCT06084936· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Avacostar - (PASS)

  NCT05897684· Vifor Fresenius Medical Care Renal Pharma· Source

• Recruiting

  Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

  NCT05848765· Phase 2· University of Birmingham· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  Adult SMA Research and Clinical Hub

  NCT06978985· Newcastle-upon-Tyne Hospitals NHS Trust· Source

• Recruiting

  Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers

  NCT05604963· University College, London· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Active, not recruiting

  COVID-19 Antibody Responses In Cystic Fibrosis

  NCT04863573· Queen's University, Belfast· Source

• Active, not recruiting

  Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

  NCT05112237· Tenaya Therapeutics· Source

• Active, not recruiting

  Preventing Recurrent Cardioembolic Stroke (The PRECISE Study)

  NCT06767189· University of Glasgow· Source

• Active, not recruiting

  A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

  NCT04969835· Phase 1· Avacta Life Sciences Ltd· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Recruiting

  iCorMicA - Stratified Medicine in Angina

  NCT04674449· NHS Greater Glasgow and Clyde· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

  NCT04640623· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04384484· Phase 3· ADC Therapeutics S.A.· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308· Phase 3· AbbVie· Source

• Active, not recruiting

  A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

  NCT03821610· Phase 2· University of Birmingham· Source

• Active, not recruiting

  A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

  NCT03539744· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03568318· Phase 3· AbbVie· Source

• Active, not recruiting

  Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.

  NCT03317990· University College, London· Source

• Active, not recruiting

  Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197· Phase 3· Pfizer· Source

• Active, not recruiting

  IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

  NCT03194815· Phase 2· University of Cambridge· Source

• Active, not recruiting

  A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

  NCT02130362· AbbVie· Source

• Active, not recruiting

  TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)

  NCT01888601· University College, London· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Dilated cardiomyopathy2 recruiting
• Pancreatic cancer2 recruiting
• Stroke2 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Spinal muscular atrophy1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Withdrawn

  Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease Population

  NCT07299682· University of Hull· Source

• Completed

  Virtual Reality Upper Limb Therapy for People With Spinal Cord Injury

  NCT06154122· Glasgow Caledonian University· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

  NCT05748483· Phase 3· AbbVie· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  AI Assisted Reader Evaluation in Acute Computed Tomography (CT) Head Interpretation

  NCT06018545· Oxford University Hospitals NHS Trust· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· AbbVie· Source

• Terminated

  A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

  NCT05678257· Phase 2· NuCana plc· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Completed

  Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

  NCT05278975· Phase 1/2· RS Oncology LLC· Source

• Completed

  Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes

  NCT05009602· Imperial College London· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

  NCT04435600· Phase 3· AbbVie· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Completed

  (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

  NCT03580655· Phase 2· Blueprint Medicines Corporation· Source

• Completed

  Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

  NCT03837977· Phase 2· The Christie NHS Foundation Trust· Source

• Recruiting

  Cardiopulmonary Toxicity of Thoracic Radiotherapy

  NCT03978377· University Medical Center Groningen· Source

• Completed

  Lowering Events in Non-proliferative Retinopathy in Scotland

  NCT03439345· Phase 4· University of Oxford· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

  NCT03104374· Phase 3· AbbVie· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Alopecia areata4 works · 1 trial